Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Laura Metrock
Assistant Professor
Close
E-mail
kmetrock@uab.edu
Visualizations
Co-investigator Network
Laura Metrock
Assistant Professor
Positions
Assistant Professor (P)
,
Pediatric - Hematology-Oncology
,
Pediatrics
2018 -
Research
Background
Contact
Research
Principal Investigator On
Private Grant
awarded by
SPRINGWORKS THERAPEUTICS
2020 - 2025
Private Grant
awarded by
NOVARTIS PHARMACEUTICALS CORPORATION
2019 - 2021
Private Grant
awarded by
ONCOCEUTICS INC
2019 - 2020
Investigator On
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2019 - 2025
Per Case Reimbursement COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2019 - 2025
Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2019 - 2025
Cookies for Kids' Cancer Phase 1 Supplemental
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2017 - 2025
Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2019 - 2024
Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2023
ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2017 - 2022
Headstart IV Clinical Study Rider
awarded by
NATIONWIDE CHILDREN'S
2017 - 2022
ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2022
ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2022
ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2022
ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2021
Phase 1-11 Study of MEK 162 for Children with Progressive or Recurrent Cancer and A Phase 11 Study of Children with Low- Grade Gliomas and Other Ras/ RAF/MAP Pathway Activated Tumors
awarded by
CHILDREN'S HOSPITAL LA
2017 - 2021
ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2017 - 2020
ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
2018 - 2019
Background
Education And Training
Doctor of Medicine,
Medical College of Georgia
2010
Contact
Full Name
Laura
Metrock